|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Frenette C and Gish RG: Hepatocellular
carcinoma: molecular and genomic guideline for the clinician. Clin
Liver Dis. 15:307–321. vii–x. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeh FS, Yu MC, Mo CC, et al: Hepatitis B
virus, aflatoxins, and hepatocellular carcinoma in southern
Guangxi, China. Cancer Res. 49:2506–2509. 1989.PubMed/NCBI
|
|
4
|
Yao D, Jiang D, Huang Z, et al: Abnormal
expression of hepatoma specific gamma-glutamyl transferase and
alteration of gamma-glutamyl transferase gene methylation status in
patients with hepatocellular carcinoma. Cancer. 88:761–769. 2000.
View Article : Google Scholar
|
|
5
|
Yao M, Yao DF, Bian YZ, et al: Oncofetal
antigen glypican-3 as a promising early diagnostic marker for
hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
10:289–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li S, Yao DF, Wang L, et al: Expression
characteristics of hypoxia-inducible factor-1α and its clinical
values in diagnosis and prognosis of hepatocellular carcinoma.
Hepat Mon. 11:821–828. 2011.
|
|
7
|
Alison MR, Nicholson LJ and Lin WR:
Chronic inflammation and hepatocellular carcinoma. Recent Results
Cancer Res. 185:135–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas MB and Zhu AX: Hepatocellular
carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gonzalez SA and Keeffe EB: Diagnosis of
hepatocellular carcinoma: role of markers and liver biopsy. Clin
Liver Dis. 15:297–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DuBray BJ Jr, Chapman WC and Anderson CD:
Hepatocellular carcinoma: a review of the surgical approaches to
management. Mo Med. 108:195–198. 2011.PubMed/NCBI
|
|
11
|
Portolani N, Baiocchi GL, Coniglio A, et
al: Limited liver resection: a good indication for the treatment of
hepatocellular carcinoma in elderly patients. Jpn J Clin Oncol.
41:1358–1365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimizu I, Yao DF, Horie C, et al:
Mutations in a hydrophilic part of the core gene of hepatitis C
virus in patients with hepatocellular carcinoma in China. J
Gastroenterol. 32:47–55. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Block TM, Mehta AS, Fimmel CJ and Jordan
R: Molecular viral oncology of hepatocellular carcinoma. Oncogene.
22:5093–5107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Malenstein H, van Pelt J and Verslype
C: Molecular classification of hepatocellular carcinoma anno 2011.
Eur J Cancer. 47:1789–1797. 2011.PubMed/NCBI
|
|
15
|
Sharma M, Ownbey RT and Sharma MC: Breast
cancer cell surface annexin II induces cell migration and
neoangiogenesis via tPA dependent plasmin generation. Exp Mol
Pathol. 88:278–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng L, Foley K, Huang L, et al: Tyrosine
23 phosphorylation-dependent cell-surface localization of annexin
A2 is required for invasion and metastases of pancreatic cancer.
PLoS One. 6:e193902011. View Article : Google Scholar
|
|
17
|
Mohammad HS, Kurokohchi K, Yoneyama H, et
al: Annexin A2 expression and phosphorylation are up-regulated in
hepatocellular carcinoma. Int J Oncol. 33:1157–1163.
2008.PubMed/NCBI
|
|
18
|
Zhao P, Zhang W, Tang J, et al: Annexin II
promotes invasion and migration of human hepatocellular carcinoma
cells in vitro via its interaction with HAb18G/CD147. Cancer Sci.
101:387–395. 2010. View Article : Google Scholar
|
|
19
|
Bao H, Jiang M, Zhu M, et al:
Overexpression of Annexin II affects the proliferation, apoptosis,
invasion and production of proangiogenic factors in multiple
myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayes MJ, Longbottom RE, Evans MA and Moss
SE: Annexinopathies. Subcell Biochem. 45:1–28. 2007. View Article : Google Scholar
|
|
21
|
Gerke V and Moss SE: Annexins: from
structure to function. Physiol Rev. 82:331–371. 2002.PubMed/NCBI
|
|
22
|
Zhang HJ, Yao DF, Yao M, et al: Expression
characteristics and diagnostic value of annexin A2 in
hepatocellular carcinoma. World J Gastroenterol. 18:5897–5904.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohno Y, Izumi M, Kawamura T, et al:
Annexin II represents metastatic potential in clear-cell renal cell
carcinoma. Br J Cancer. 101:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruan J, Liu F, Chen X, et al: Inhibition
of glypican-3 expression via RNA interference influences the growth
and invasive ability of the MHCC97-H human hepatocellular carcinoma
cell line. Int J Mol Med. 28:497–503. 2011.PubMed/NCBI
|
|
25
|
Yoon SY, Kim JM, Oh JH, et al: Gene
expression profiling of human HBV- and/or HCV-associated
hepatocellular carcinoma cells using expressed sequence tags. Int J
Oncol. 29:315–327. 2006.
|
|
26
|
Tazi el M, Essadi I, M’rabti H, et al:
Systemic treatment and targeted therapy in patients with advanced
hepatocellular carcinoma. N Am J Med Sci. 3:167–175.
2011.PubMed/NCBI
|
|
27
|
Grewal T and Enrich C: Annexins -
modulators of EGF receptor signalling and trafficking. Cell Signal.
21:847–858. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao M, Yao DF, Bian YZ, et al: Values of
circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients
with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
12:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
